LONDON and NEW YORK - OKYO Pharma Limited (NASDAQ: OKYO), a biopharmaceutical company specializing in the development of treatments for ocular conditions and currently valued at $37 million, has ...

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an ...

GRAND FORKS — A Grand Forks man is celebrating the success of a relatively new procedure for amputees, which has changed his ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

In the second world war, the physician Henry Beecher observed that some of his soldier patients, despite being injured on the ...

In recent years, the conversation surrounding cannabis and its medicinal properties has gained considerable momentum.

Patients can now receive interventional techniques that are no longer palliative in nature,” stated Samir Khan, DO, provider ...

As an orthopedic and sports medicine surgeon and chairman at Inova Sports Medicine, Dr. Robin West is no stranger to sports-related injuries. She understands that developing an effective game plan to ...

The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced that it has received a U.S. patent for the treatment. AV-101 (4-Cl-KYN) is ...

The US Patent and Trademark Office (USPTO) has granted a patent to Vistagen’s non-opioid oral product candidate, AV-101 for ...

Scratching an itchy rash worsens inflammation by triggering pain-sensing neurons and activating mast cells, creating a ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.